ALX Oncology Holdings Inc. Common Stock (ALXO)

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Ev…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

48

Website

alxoncology.com/

Fundamentals

1-day range

$1.98$2.04

Market cap

$259.71M

P/E (trailing)

—

P/E (forward)

-3.72

EPS (trailing)

$-1.49

Dividend yield

—

Beta

0.46

Avg. volume

1.32M

Forecasts

5 analyst ratings

ALX Oncology Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ALXO

  ALX Oncology Holdings Inc. Common Stock

  $2

  ▼ 2.44%
  Market cap $259.71MP/E —
  $0.96$2.66
• VRXA

  Veraxa Biotech AG Ordinary Shares

  $1.36

  ▼ 5.56%
  Market cap $258.78MP/E —
  $1.32$27.36
• ELDN

  Eledon Pharmaceuticals Inc. Common Stock

  $3.19

  ▼ 3.92%
  Market cap $264.75MP/E —
  $1.35$4.6
• IMRX

  Immuneering Corporation Class A Common Stock

  $4.99

  ▼ 4.22%
  Market cap $269.79MP/E —
  $3.86$10.08
• BCYC

  Bicycle Therapeutics plc American Depositary Shares

  $4.21

  ▼ 2.77%
  Market cap $270.87MP/E —
  $3.75$9.16
• MGNX

  MacroGenics Inc. Common Stock

  $4.13

  ▲ 1.23%
  Market cap $242.81MP/E —
  $1.29$5.08
• ADAG

  Adagene Inc. American Depositary Shares

  $3.68

  ▼ 5.64%
  Market cap $239.77MP/E —
  $1.3$4.85

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
  Benzinga · 8/6/2026

• Wong Shelly · July 1, 2026 · Sale

  1.4K @ $2.04
• Knight Jeff E. · April 16, 2026 · Grant

  800.0K
• Barbara Klencke · April 16, 2026 · Grant

  100.0K
• Shelly Pinto · March 19, 2026 · Sale

  903 @ $2.17
• Jason Lettmann · March 19, 2026 · Sale

  12.3K @ $2.17
• Barbara Klencke · March 3, 2026 · Grant

  700.0K

Institutional Ownership

March 31, 2026

Total shares held

93.94M

Total value held

$186.01M

Institutional holders

66